Navigation Links
BiologicsMD, Inc. Announces Issuance of Patent for PTH-CBD™ in Japan
Date:8/14/2014

Fayetteville, Arkansas (PRWEB) August 14, 2014

BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the Japanese Patent Office issued Patent No. 5520811, entitled "Delivery of Therapeutic Agents by a Collagen Binding Protein," to The Board of Trustees of the University of Arkansas (U.S.), Kitasato University (Japan), and the Montefiore Medical Center (U.S.). This patent supports the U.S. patent issued in 2013 (U.S. Patent No. 8,450,273), entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone." BiologicsMD™ is the exclusive licensee of the patent.

BiologicsMD is developing PTH-CBD™ to accelerate the rate of bone fracture repairs and reduce the number of fracture non-unions. Despite current surgical techniques and advanced surgical hardware, further clinical advances are needed to reduce the number of incomplete unions, provide faster fracture healing, and greatly reduce the need for secondary interventions and additional surgeries.

"BiologicsMD is pleased to receive this additional composition of matter patent issued in Japan, and we are looking forward to the remaining patent applications being issued worldwide," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has a unique profile of selective targeting and strong osteogenic/anabolic properties which enables us to foresee a highly differentiated new product to help treat human disease.”

BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD selectively binds to type I collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. This CBD-derived targeting also provides for a long-acting therapeutic, thereby enabling semi-annual dosing for chronic disorders. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12094978.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. BiologicsMD, Inc. Announces Issuance of First U.S. Patent for PTH-CBD™
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 Australian-US drug discovery and development company, Novogen ... of a new Chairman, Mr John O,Connor , and ... James Garner , has also been formally ... Acting CEO, Mr Iain Ross , will resume his ... James Garner , has also been formally appointed to ...
(Date:2/4/2016)... ... 2016 , ... Shimadzu Scientific Instruments will showcase several new ... poster sessions, and present on the analysis of mycotoxins and medical cannabis at ... 10 at the Georgia World Congress Center in Atlanta, Georgia. , Attendees ...
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development and commercialization ... at the 18 th Annual BIO CEO & ... a.m. EST in New York, NY . ... will provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... 4, 2016 Sinovac Biotech Ltd. ("Sinovac" or ... of biopharmaceutical products in China , ... of directors received on February 4, 2016 a preliminary ... consortium comprised of PKU V-Ming ( Shanghai ... CICC Qianhai Development ( Shenzhen ) Fund ...
Breaking Biology Technology:
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
Breaking Biology News(10 mins):